Remix Therapeutics

Following the FDA’s Rare Disease Framework Initiative Public Meeting, our CEO Pete Smith shares why scientific rigor and collaboration are essential to advancing new treatment options for rare disease communities.
Read more: bit.ly/3W7X4Hu

REM-422 will be featured in a late-breaking oral presentation at #ENA2026, highlighting updated interim Phase 1/2 ARIA data in ACC. We look forward to sharing the latest findings on our potentially first-in-class oral MYB mRNA degrader.
bit.ly/47JImZK
#Oncology #ACC

Welcome Michael Landsittel to the Remix BoD!

Michael brings 20+ years of biotech leadership experience, most recently as CFO of Blueprint Medicines. We're excited to benefit from Michael's expertise as we advance RNA-targeted medicines for patients.

Learn more: bit.ly/4j1sYPf

At #DrugDiscoveryOnTarget, our CSO, Dominic Reynolds, will highlight REM-422, our first-in-class mRNA degrader targeting the MYB oncogene, and discuss how our REMaster® platform is enabling new approaches to previously undruggable RNA targets.

#RNATherapeutics #DrugDiscovery

Please join us in welcoming Tony Mullin as our new Chief People Officer.

Tony has led people strategies at Omega Therapeutics, Pandion Therapeutics and Biogen, creating cultures that support innovation, growth and impact.

We're thrilled to have him on #TeamRemix.